A Study of IBI363 in Subjects With Advanced Malignancies

PHASE1RecruitingINTERVENTIONAL

Enrollment

556

Participants

Timeline

Start Date

June 15, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2026

Conditions

Advanced Malignancies

Interventions

DRUG

IBI363 + chemotherapy

In this group, patients will receive IBI363 and chemotherapy

DRUG

IBI363 + Investigator's Choice SOC

In this group, patients will receive IBI363 and Investigator's Choice SOC

Trial Locations (1)

RECRUITING

Shanghai Chest Hospita, Shanghai

All Listed Sponsors

lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT06468098 - A Study of IBI363 in Subjects With Advanced Malignancies | Biotech Hunter | Biotech Hunter